Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer

By Ma Dong. 2006

1,338 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/f397b6cf732d4422a9ca6176a10b48dc3b02c123

Citations in the corpus

• Ranibizumab in neovascular age-related macular degeneration (2006, unknown): “Pegaptanib and ranibizumab for neovascular AMD (see above) and bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA), a recombinant, monoclonal antibody to VEGF, approved for treatment of metastatic colorectal cancer (Hurwitz et al 2004).”
• Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer (2022, unknown): “Moreover, several studies have demonstrated that fl uorouracil-based ACT in combination with bevacizumab can extend OS in CRC patients relative to those receiving fl uorouracil-based ACT alone 35,36 .”
• VEGF as a Therapeutic Target in Cancer (2005, unknown): “In a large randomized controlled trial, the addition of bevacizumab to standard chemotherapy for patients with previously untreated metastatic CRC resulted in a 30% increase in median survival (Hurwitz et al. 2004 [27] , described in more detail later in this issue).”